Drug Combo Disappoints as Second-line Therapy for Advanced NSCLC with EGFR and T790M Mutations
May 24, 2021, 6:25 pm
Second-line bevacizumab plus osimertinib showed some PFS benefit over osimertinib alone in a subset of smokers/former smokers but overall showed no survival benefits in the ETOP BOOSTER trial.
